DRMA:NASDAQ, Dermata Therapeutics, Inc.
DRMA stock overview
Dermata Therapeutics, Inc. (DRMA:NASDAQ) closed at $0.599 on November 16, 2026,
down 3.65% on the day.
The stock trades 87.2% below its 52-week high of $4.66
and 5.7% above its 52-week low of $0.566.
Over the past year, it lost 77.6%.
Dermata Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $0.599
- Day change
- -3.65%
- Volume
- 48,756
- Average volume
- 2,792,995
- Market cap
- 2M+
- 52-week range
- $0.566 – $4.66
- 50-day average
- $0.967
- 200-day average
- $1.23
Price action over the past year
In 252 trading sessions since November 14, 2025, DRMA closed higher on 101 days (40%).
Its best day was February 19, 2026 (+50.78%) and its worst was February 20, 2026 (-30.05%).
The stock moved 10% or more in a single session 32 times.
It opened at least 5% above the previous day's high 5 times.
Recent signals
DRMA news
-
Nov 10, 2026:
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
-
Nov 5, 2026:
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
-
Oct 29, 2026:
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
-
Oct 15, 2026:
BC-Most Active Stocks
-
Oct 15, 2026:
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Aug 31, 2026:
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
-
Aug 25, 2026:
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
-
Aug 21, 2026:
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
About Dermata Therapeutics, Inc.
Dermata Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.
Similar stocks
Find more stocks like DRMA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.